LTI-03
LTI-03-2001 (RENEW)
Phase 2 small_molecule active
Quick answer
LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) is a Phase 2 program (small_molecule) at Rein Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rein Therapeutics
- Indication
- Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active